Pharmacovigilance is one of the elements assessed during the procedure of granting marketing authorization and continues to be monitored throughout the entire life cycle of a medicinal product. The present work provides a comparative analysis of innovative medicinal product marketing authorizations granted by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), focusing on therapeutic indications and pharmacovigilance requirements. The study examines 15 medicinal products jointly approved by both agencies in 2024, exploring similarities and differences in authorized indications, safety profiles, and risk minimization measures, including risk management plans (RMPs) and risk evaluation and mitigation strategies (REMS). The analysis reveals a high degree of harmonization, but also differences in risk classification, the application of digital tools, and the regulatory documentation requirements. The findings underline the need for ongoing harmonization and the adoption of best practices in pharmacovigilance to support optimal patient safety outcomes.
Kostov E, Grigorov E, Belcheva V, Hristova P. REVIEW OF THE HISTORICAL ASPECTS IN THE DEVELOPMENT OF CLINICAL TRIALS. Asklepii: Bolgaro-sovetskii Ezhegodnik Istorii i Teorii Meditsiny. 2013 Dec 1;8:39–46.
Vekov T, Petrova G, Stefanova L, L.Miteva, Kolev J. A COMPARATIVE ANALYSIS OF THE US AND EU DRUG REGULATORY PROCESS. Медицински мениджмънт и здравна политика. 2024 Mar 4;55:17–32.
Getova V, Getov I. Analysis of marketing authorization procedures with negative opinion 2020-2021 – how EMA handled challenges in drug therapy during Covid-19 pandemic. Annual for Hospital Pharmacy. 2021 Oct 14;7(1):13–9.
European Medicines Agency. ICH guideline E19 on a selective approach to safety data collection in specific late-stage pre-approval or postapproval clinical trials. [Internet] [cited 2025 Jun 19]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e19-selective-approach-safety-data-collection-specific-late-stage-pre-approval-or-post-approval-clinical-trials-step5_en.pdf
International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. ICH Harmonised Tripartite Guideline - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A [Internet] [cited 2025 Jun 19]. Available from: https://brill.com/view/book/edcoll/9789004181564/Bej.9789004163300.i-1081_085.xml
Stoynova V., Lebanova H., Grigorov E.. Adverse drug reactions under reporting factors characteristics’ in Bulgaria – an overview. Здравна политика и мениджмънт. 2011;(4):97–102.
European Medicines Agency. Risk management plans. [Internet] [cited 2025 Jun 19]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pharmacovigilance-marketing-authorisation/risk-management/risk-management-plans
Food and Drug Administration. Risk Evaluation and Mitigation Strategies | REMS. [Internet] [cited 2025 Jun 19] Available from: https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
Chapman, S., G. Dedet and R. Lopert. Shortages of medicines in OECD countries. OECD Health Working Papers. 2022; No. 137.
Kashoki M, Hanaizi Z, Yordanova S, Veselý R, Bouygues C, Llinares J, et al. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014–2016: Concordance, Discordance, and Why. Clin Pharmacol Ther. 2020 Jan;107(1):195–202.
Smith MY, Frise S, Feron J, Marshall R. Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom. Drug Saf. 2022;45(3):259–74.
Gavriilaki E. Hematology: the specialty with a record number of new approvals. Frontiers in Medicine. 2024; 11.
Franco P, Jain R, Rosenkrands-Lange E, Hey C, Koban MU. Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries. Ther Innov Regul Sci. 2023 May 1;57(3):484–514.
Abraham J. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Tietje C, Brouder A, editors. Handbook of Transnational Economic Governance Regimes [Internet]. Brill | Nijhoff; 2010 [cited 2025 Jun 19]. p. 1041–53. Available from: https://brill.com/view/book/edcoll/9789004181564/Bej.9789004163300.i-1081_085.xml
European Medicines Agency. Good pharmacovigilance practices (GVP). [Internet] [cited 2025 Jun 19]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
Food and Drug Administration. Guidance for Industry - Premarketing Risk Assessment. [Internet]. [cited 2025 Jun 19]. Available from: https://www.fda.gov/media/71650/download
Food and Drug Administration. Guidance for Industry - Development and Use of Risk Minimization Action Plans. [Internet]. [cited 2025 Jun 19]. Available from: https://www.fda.gov/media/71268/download
Food and Drug Administration. Guidance for Industry - Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. [Internet]. [cited 2025 Jun 19]. Available from: https://www.fda.gov/media/71546/download
European Federation of Pharmaceutical Industries and Associations. The root causes of unavailability of innovative medicines and delay in access: Shortening the wait. [Internet]. [cited 2025 Jun 19]. Available from: https://www.efpia.eu/media/xsmfuf4h/root-causes-of-unavailability-and-delay-efpia-cra-2024.pdf
Email this article (Login required) 
